Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery

Cancer Cell. 2004 May;5(5):477-88. doi: 10.1016/s1535-6108(04)00116-3.

Abstract

We show that mouse embryonic endothelial progenitor cells (eEPCs) home preferentially to hypoxic lung metastases when administered intravenously. This specificity is inversely related to the degree of perfusion and vascular density in the metastasis and directly related to local levels of hypoxia and VEGF. Ex vivo expanded eEPCs that were genetically modified with a suicide gene specifically and efficiently eradicated lung metastases with scant patent blood vessels. eEPCs do not express MHC I proteins, are resistant to natural killer cell-mediated cytolysis, and can contribute to tumor vessel formation also in nonsyngeneic mice. These results indicate that eEPCs can be used in an allogeneic setting to treat hypoxic metastases that are known to be resistant to conventional therapeutic regimes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / pathology
  • Bone Neoplasms / therapy
  • Bystander Effect
  • Carcinoma, Lewis Lung / metabolism
  • Carcinoma, Lewis Lung / pathology
  • Carcinoma, Lewis Lung / therapy
  • Cell Hypoxia*
  • Cytosine Deaminase / genetics
  • Cytosine Deaminase / metabolism
  • Embryonic and Fetal Development / physiology*
  • Endothelium, Vascular / embryology*
  • Endothelium, Vascular / metabolism
  • Fluorouracil / metabolism
  • Gene Targeting
  • Genes, Transgenic, Suicide*
  • Genetic Therapy
  • Genetic Vectors
  • Injections, Intravenous
  • Killer Cells, Natural / metabolism
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / secondary*
  • Lung Neoplasms / therapy*
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Neovascularization, Pathologic / prevention & control
  • Osteosarcoma / metabolism
  • Osteosarcoma / pathology
  • Osteosarcoma / therapy
  • Pentosyltransferases / genetics
  • Pentosyltransferases / metabolism
  • Prodrugs / metabolism
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacology
  • Stem Cells / physiology*
  • Survival Rate
  • Uracil / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Prodrugs
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • Uracil
  • Pentosyltransferases
  • uracil phosphoribosyltransferase
  • Cytosine Deaminase
  • Fluorouracil